InMode Ltd. (NASDAQ:INMD) is one of the best undervalued medical device stocks to buy now. In a report released on July 10, Caitlin Cronin from Canaccord Genuity maintained a Hold rating on InMode Ltd. (NASDAQ:INMD) and set a price target of $15.00.
A medical professional wearing gloves and a protective mask performing a minimally invasive aesthetic medical procedures on a patient.
InMode Ltd. (NASDAQ:INMD) announced in its fiscal Q1 2025 results that it decided to revise its full-year guidance due to continuous uncertainty regarding the US economic outlook and persistent market weakness.
Based on the preliminary results, InMode Ltd. (NASDAQ:INMD) expects non-GAAP gross margin for fiscal Q2 2025 to be in the 79% to 80% range, and revenue to be in the range of $95.4 million to $95.5 million.
The company expects full-year revenue for 2025 to be in the range of $365 million to $375 million, compared to prior guidance of $395 million to $405 million.
InMode Ltd. (NASDAQ:INMD) develops, designs, manufactures, and markets minimally invasive aesthetic medical products used for a number of procedures, such as wrinkle reduction, permanent hair reduction, facial skin rejuvenation, cellulite treatment, pigmented lesions, and more.
While we acknowledge the potential of INMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
